Phase 2/3 - COVID-19 related hospitalization or all-cause death through Day 29 - Assessment of safety through Day 29 based on: o The incidence of TEAEs o Incidence of solicited injection site reactions through Day 4 o Changes from baseline in clinical laboratory tests (ie, CBC with differential, serum chemistry, coagulation) o Changes from baseline in vital signs (body temperature, heart rate, respiration rate, and systolic and diastolic blood pressure)

Phase 2/3 - COVID-19 related hospitalization or all-cause death through Day 29 - Assessment of safety through Day 29 based on: o The incidence of TEAEs o Incidence of solicited injection site reactions through Day 4 o Changes from baseline in clinical laboratory tests (ie, CBC with differential, serum chemistry, coagulation) o Changes from baseline in vital signs (body temperature, heart rate, respiration rate, and systolic and diastolic blood pressure)